VANCOUVER, BC, Aug. 18, 2022 /CNW/ – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life“) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that it has closed the initial tranche (the “First Tranche“) of its financing commitment (the “Financing“) by Alpha…


Previous articleBright Minds Biosciences Comments on Recent Trading Activity
Next articlePT348 – Steve DeAngelo – Cannabis and Psychedelics: Industry, Consciousness, Justice, and Joy